Skip to main content

RAPID MICRO BIOSYSTEMS INC

For the period ended Dec 31, 2023. Filed Mar 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 1, 2024

RPID$0.73+13.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

RAPID MICRO BIOSYSTEMS, INC.
Date: March 1, 2024By:/s/ Robert Spignesi
Robert SpignesiPresident and Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

Each person whose individual signature appears below hereby authorizes and appoints Robert Spignesi and Sean Wirtjes, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by thefollowing persons on behalf of the registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Robert SpignesiPresident, Chief Executive Officer and DirectorMarch 1, 2024
Robert Spignesi(principal executive officer)
/s/ Sean WirtjesChief Financial OfficerMarch 1, 2024
Sean Wirtjes(principal financial officer and principal accounting officer)
/s/ Kirk D. Malloy, Ph.D.Chair of the Board of DirectorsMarch 1, 2024
Kirk D. Malloy, Ph.D.
/s/ David Hirsch, M.D., Ph.D.DirectorMarch 1, 2024
David Hirsch, M.D., Ph.D.
/s/ Richard KollenderDirectorMarch 1, 2024
Richard Kollender
/s/ Melinda LitherlandDirectorMarch 1, 2024
Melinda Litherland
/s/ Inese LowensteinDirectorMarch 1, 2024
Inese Lowenstein
/s/ Natale RicciardiDirectorMarch 1, 2024
Natale Ricciardi
/s/ Jeffrey SchwartzDirectorMarch 1, 2024
Jeffrey Schwartz
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.